Track the Quince Therapeutics, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €29.5m. The latest transaction was disclosed on 29 December 2025 (J). Among the most active insiders: Thye Dirk. Every trade is free.
24
Insider Decl.
n/a
Thresholds
€568,671
12 ops.
Buy Volume
€148,942
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Quince Therapeutics, Inc. Buy (bullish), based on 4 analysts. Average price target: US$82.75.
50Σ signal
Buys €568,671€148,942 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
1,520 shares@ US$1.6447.0% of flowCommon StockSEC:0001209191-22-049221:0
24 of 24 declarations
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. It employs innovative approaches to enhance the quality of life for patients.